(IN BRIEF) Researchers at The Institute of Cancer Research and Queen Mary University have created EIRAs, a computational assay that predicts how bowel cancer cells evolve resistance to chemotherapy. By monitoring cell populations and applying evolutionary models, the tool differentiates … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged bowel cancer, breast cancer, Cancer Research UK, chemotherapy resistance, colorectal cancer, drug discovery, EIRAs, evolutionary biology, Evolutionary Informed Resistance Assays, Freddie Whiting, genetic mutation, Kristian Helin, Machine Learning, Nature Communications, non-genetic adaptation, ovarian cancer, patent, personalized therapy, Queen Mary University of London, Richard Nichols, The Institute of Cancer Research London, Trevor Graham, Wellcome Trust
(IN BRIEF) The University of Copenhagen, in collaboration with Rigshospitalet, has introduced a clinically validated gene-editing method to identify harmful inherited mutations that raise cancer risk. Developed at the university’s Biotech Research and Innovation Center, the CRISPR-Select technique allows scientists … Read the full press release
Posted in Denmark, Education, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged BRCA2, breast cancer, BRIC, cancer diagnosis, cancer risk, CRISPR-Select, gene editing, genetic testing, genomic medicine, hereditary cancer, Maria Rossing, ovarian cancer, personalized medicine, Rigshospitalet, The Journal of Clinical Investigation, University of Copenhagen, variant classification
(IN BRIEF) Researchers from the University of Copenhagen have made a breakthrough in the biosynthetic production of Taxol, a widely used chemotherapy drug. By identifying the enzymes responsible for the final steps in the biosynthetic pathway of Taxol, the team … Read the full press release
Posted in Business, Denmark, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged biosynthetic production, biotechnology, cancer treatment, chemotherapy, environmental sustainability, Feiyan Liang, ovarian cancer, Pacific yew tree, pharmaceutical innovation, Sotirios Kampranis, sustainable drug production, sustainable medicine, Taxol, University of Copenhagen
(IN BRIEF) Aviva’s recent research, conducted during Ovarian Cancer Awareness Month, reveals significant gaps in the knowledge of ovarian cancer symptoms among UK women. The study found that 62% of women overall, and 73% of those over 55, feel … Read the full press release
Posted in Healthcare, Insurance, Society, United Kingdom
Tagged 400 cases by 2040, 500 new cases, 53% increase, 62% lack knowledge, 7, 73% over 55, 9, 91% claims over 40, age, Aviva, Aviva UK Health, awareness, bloating, BRCA1, BRCA2, delayed GP consultation, Diabetes, diagnostic tests, Dr Suba M, genetic mutations, irritable bowel syndrome, ovarian cancer, pelvic examination, smear test misconception, stomach bug, swollen abdomen, symptoms, UK women, £6.4 million claims
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, inhibitor, Japan, Lynparza, Lynparza (olaparib), ovarian cancer, PARP, Roy Baynes
First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women Darmstadt, Germany and New York, US, 07-Jul-2016 … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged Merck, ovarian cancer, Pfizer, Phase III study JAVELIN Ovarian 100
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer BASEL, 13-8-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EU) approved the … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?